Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer

Kategoria artykułu: Research Article

Data publikacji: 07 kwi 2022

Zakres stron: 185 - 197

Otrzymano: 26 wrz 2021

Przyjęty: 28 sty 2022

DOI: https://doi.org/10.2478/raon-2022-0012

Słowa kluczowe

vactosertib, transforming growth factor-β (TGF-β), radiotherapy, epithelial-to-mesenchymal transition, cancer stem cell, breast cancer

© 2022 Jiwon Choi, Jiyoung Park, Ilyoung Cho, Yhunyhong Sheen, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.